Aclaris Therapeutics Inc (NASDAQ:ACRS)

14.43
Delayed Data
As of Jun 24
 -1.42 / -8.96%
Today’s Change
9.26
Today|||52-Week Range
19.97
-0.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$960.1M

Company Description

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Contact Information

Aclaris Therapeutics, Inc.
640 Lee Road
Wayne Pennsylvania 19087
P:(484) 324-7933
Investor Relations:

Employees

Shareholders

Other institutional56.27%
Individual stakeholders38.51%
Mutual fund holders18.74%

Top Executives

Neal S. WalkerPresident, Chief Executive Officer & Director
Frank RuffoChief Financial Officer, Secretary & Treasurer
Joseph B. MonahanChief Scientific Officer
Monica SalameaVice President-Clinical Operations
James LoeropChief Business Officer